ARCHIVES

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

This article is from The Cancer Letter archive.

Vol. 25 No. 06 | February 12, 1999

Download PDF Visit The Full Archive

Related Articles

Annual Report Key Element In Prevention Drive, Maquire Insists

February 2, 1979

Low-Dose IFN Not Effective Against Melanoma, Study Finds

December 26, 2003

60 Minutes Report “Deception at Duke” Wins Peabody Award

March 29, 2013

Consolidation Unlikely to Save Money

December 17, 2010

Ohio State Wins P01 Grant

December 6, 2002

Bristol-Myers Awards 42.5 Million In Cancer Grants

October 21, 1977